STEMI
Conditions
Interventions
BNP group:Intravenous rhBNP
1.5ug/kg iv, followed by intravenous infusion of 0.0075ug/kg/min of BNP continued for 48h
Control group:Intravenous Placebo
Placebo
1.5ug/kg iv, followed by intravenous infusion of 0.0075ug/kg/min of Placebo continued for 48h
Sponsors
Shanghai Renji Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Criteria for study entry were age over 18 years; Ischemic type chest pain of >30 min duration; ST-segment elevation in at least 2 contiguous ECG leads with the cut-off points =0.2 mV in leads V1, V2 or V3 and =0.1 mV in other leads; Admission to hospital within 12 h of the onset of symptoms.
Exclusion criteria
Exclusion criteria: Exclusion criteria were systolic blood pressure <90 mm Hg (including cardiogenic shock) or requirement for mechanical support (intra-aortic balloon pumping, mechanical ventilation, or both); A history of myocardial infarction; previous coronary artery bypass grafting; A culprit lesion in the left main coronary artery, distal artery or small branch; Rescue intervention after failed thrombolysis; A known allergic reaction to rhBNP; severe liver, renal, or brain dysfunction; Life-limiting noncardiac disease (e.g., advanced cancer, end-stage pulmonary disease); Suspected aortic dissection; and pregnancy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| WMSI in Echocardiography;The TIMI myocardial perfusion grade (TMPG); | — |
Secondary
| Measure | Time frame |
|---|---|
| Thrombolysis In Myocardial Infarction (TIMI) trial;Resolution of ST-segment elevation on ECG;Neurohormonal factors(rennin, angiotensin II, aldo;ET-1, BNP;adrenomedullin, epinephrine, norepinephrine);The corrected TIMI frame count(CTFC);Ventricular remodelling in Echocardiography;Cardiac marker enzymes;Major adverse cardiac events (MACE); | — |
Countries
China
Contacts
Public ContactBen HE; Jun PU
Outcome results
None listed